Szyman Catherine M.

About Szyman Catherine M.

Catherine M. Szyman is an experienced medical technology executive with a career spanning strategy, operations, finance, and business development. Since January 2015, she has served as Corporate Vice President of Critical Care at Edwards Lifesciences Corp., a NYSE-listed company focused on innovations for structural heart disease, critical care, and surgical monitoring. In that role, she has helped lead a strategically important business area and has been associated with product and market initiatives aimed at advancing predictive and clinically useful monitoring solutions. Edwards’ communications around its critical care platform highlight her leadership in the category. ([ir.inarimedical.com](https://ir.inarimedical.com/corporate-governance/board-of-directors?utm_source=openai)) Before joining Edwards, Ms. Szyman spent more than two decades at Medtronic, where she worked from 1991 through 2014 in a series of senior leadership positions. Her roles included President of Global Diabetes, Vice President of Corporate Strategy and Business Development, Vice President and General Manager of the Endovascular business, and Vice President of Finance for the Vascular business. That track record reflects broad operational and financial leadership across a global medtech environment, with experience in business transformation, portfolio management, and growth execution in highly regulated markets. ([ir.inarimedical.com](https://ir.inarimedical.com/corporate-governance/board-of-directors?utm_source=openai)) In corporate governance, Ms. Szyman serves on the board of Outset Medical, Inc., where she is a member of the compensation committee, and she has also served as a director of Inari Medical, Inc. since November 2019. She has additionally served as a board observer for Endotronix, a private medical device company, and has held board-related roles connected to healthcare and education organizations. These roles underscore her relevance as a governance leader in the medtech sector and her ability to support companies through growth, innovation, and public-market oversight. ([ir.inarimedical.com](https://ir.inarimedical.com/corporate-governance/board-of-directors?utm_source=openai)) Overall, Ms. Szyman’s profile is defined by deep experience in medical devices, a strong record in executive leadership, and meaningful board service across public and private healthcare companies. Her expertise covers corporate strategy, business development, finance, global operations, and product commercialization, making her a notable governance figure in the U.S. healthcare market. ([ir.inarimedical.com](https://ir.inarimedical.com/corporate-governance/board-of-directors?utm_source=openai))